← All candidates
21 insider filings on record.
Gilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 29 May · filed 8 Jun · selfBuy$1K–$15Kself29 May110d ago8 Jun100d agoGilbert Ray Cisneros, Jr.Small Business · Armed Servicestraded 3 Mar · filed 7 Apr · selfBuy$1K–$15Kself3 Mar197d ago7 Apr162d ago21 filings on record.
LGNDLIGAND PHARMACEUTICALS INC
NasdaqGM · Healthcare · $5.67B
$284.47
21 insider filings on record.
None of them an open-market buy in the last year.
No price data yet — the yfinance scanner hasn't produced bars for LGND.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$5.67B
Float
19.5M
98% public
Short % float
Pro
Price / profit
29.3
Price / future profit
23.8
Price / sales
19.5
Congress
▸ Disclosures lag trades by 30–45 days.
4 disclosures12 mo
MemberTypeAmountOwnerTradedFiled
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
16 more transactions on Pro →Context
Wall St
$327.40 avg target
+15.1% vs today · 10 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$1.63 act−$0.17
Q4 '25$2.02 act+$0.52
Q3 '25$3.09 act+$1.16
Q2 '25$1.60 act+$0.18
Coverage
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On EarningsSimply Wall St. · 07-16This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026Investor's Business Daily · 07-27Shopify downgraded, Five Below upgraded: Wall Street's top analyst callsThe Fly · 07-21
The file stays open
21 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice